Immunotherapy-related hepatitis: real-world experience from a tertiary centre
<p><strong>Objective</strong> Immune checkpoint inhibitors like anti-programmed cell death protein 1 (PD-1) drugs Nivolumab and Pembrolizumab and anti-cytotoxic T-lymphocyte associated (CTLA-4) drug Ipilimumab have become standard of care in many metastatic cancers. Immunotherapy-r...
Main Authors: | Cheung, V, Gupta, T, Payne, M, Middleton, MR, Collier, JD, Simmons, A, Klenerman, P, Brain, O, Cobbold, JF |
---|---|
Format: | Journal article |
Published: |
BMJ Publishing Group
2019
|
Similar Items
-
Desmopressin prescription safety in adult inpatients: a real-world tertiary centre experience
by: Muhammad Fahad Arshad, et al.
Published: (2025-02-01) -
Real world perspective of coronary chronic total occlusion in third world countries: A tertiary care centre study from northern India
by: Krishna Santosh Vemuri, et al.
Published: (2021-03-01) -
Activation of PPCI team in the octogenarian and nonagenarians population: real-world single-centre experience
by: Samer Arnous, et al.
Published: (2021-12-01) -
“Real world” experience in cardiac resynchronisation therapy at a Swiss tertiary care centre: update 2016
by: Stephan Winnik, et al.
Published: (2017-04-01) -
Real-World Use of Immunotherapy for Hepatocellular Carcinoma
by: Sara A, et al.
Published: (2023-08-01)